2024 Çѱ¹ÁöÁúµ¿¸Æ°æÈÇÐȸ Ãá°èÇмú´ëȸ (SoLA 2024) 2ÀÏÂ÷ : 2024-04-06
±³À°ÀÏÀÚ : 2024-04-06
±³À°Àå¼Ò : ½Ã±×´Ï¿¤ ºÎ»ê 4Ãþ room1,2,3
±³À°ÁÖÁ¦ : 2024 Çѱ¹ÁöÁúµ¿¸Æ°æÈÇÐȸ Ãá°èÇмú´ëȸ (SoLA 2024) 2ÀÏÂ÷
ÁÖÃÖ±â°ü : Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈÇÐȸ
´ã´çÀÚ : SoLA2024 Áغñ»ç¹«±¹
¿¬¶ôó : 02-6734-1011
À̸ÞÀÏ : sola2024@planbear.co.kr
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀÎ : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 6 ½Ã°£ 50ºÐ
¼¼ºÎ¼ö°·á : 70,000¿ø
ºñ°í ±³¼ö/ºÀÁ÷ÀÇ/°³¿øÀÇ : »çÀü µî·Ï (ȸ¿ø) 40,000¿ø,(ºñȸ¿ø)60,000¿ø. ÇöÀå µî·Ï (ȸ¿ø)50,000¿ø, (ºñȸ¿ø)70,000 ÀüÀÓÀÇ/¿µ¾ç»ç/¿îµ¿»ç/°£È£»ç/¿¬±¸¿ø/±âŸ Âü°¡ÀÚ: »çÀüµî·Ï (ȸ¿ø)20.000¿ø,(ºñȸ¿ø)40,000¿ø ÇöÀåµî·Ï(ȸ¿ø)30,000¿ø, (ºñȸ¿ø) 50,000¿ø Çлý/Àü°øÀÇ/±ºÀÇ°ü/°øÁߺ¸°ÇÀÇ/65¼¼ ÀÌ»ó: ¹«·á
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04¿ù 06ÀÏ Room1 07:30~07:50 The lastes clinical trial of Atorvastatin, LODESTAR study Á¤Ã¢Èñ(¿ï»êÀÇ´ë ³»ºÐºñ³»°ú)
Åä·Ð 04¿ù 06ÀÏ Room1 07:50~08:00 Panel Discussion ()
±³À°½Ã°£ 04¿ù 06ÀÏ Room1 08:30~08:50 Bempedoic acid ±èÇзÉ(¼¿ïÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 04¿ù 06ÀÏ Room1 08:50~09:10 Semaglutide À±Á¾Âù(°¡Å縯ÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 04¿ù 06ÀÏ Room1 09:10~09:30 Inclisiran ÀüÀçÇÑ(°æºÏÀÇ´ë ³»ºÐºñ³»°ú)
Åä·Ð 04¿ù 06ÀÏ Room1 09:30~10:00 Panel Discussion ()
ÈÞ½Ä 04¿ù 06ÀÏ 10:00~10:15 Break ()
±âŸ 04¿ù 06ÀÏ 10:15~10:20 Opening Address ()
±³À°½Ã°£ 04¿ù 06ÀÏ Room1,2,3 10:20~11:00 Heart-Immune-Brain network in the pathogenesis of cardio-cerebrovascular disease ¿À±¸ÅÃ(ÀÌÈ¿©´ë »ý¸í°úÇаú)
±³À°½Ã°£ 04¿ù 06ÀÏ Room1 12:20~12:40 Cutting edge care of pitavastatin with ezetimibe combination therapy ¹Ú°æÀÏ(µ¿¾ÆÀÇ´ë ¼øȯ±â³»°ú)
Åä·Ð 04¿ù 06ÀÏ Room1 12:40~12:50 Panel Discussion ()
ÈÞ½Ä 04¿ù 06ÀÏ 12:50~13:20 Break ()
±³À°½Ã°£ 04¿ù 06ÀÏ Room1 13:30~13:50 KSoLA- Deciphering lipid enigmas: exploring TRL, triglycerides and remnant cholesterol as residual lipid risks and treatment targets ±èº´Áø(¼º±Õ°üÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 04¿ù 06ÀÏ Room1 13:50~14:10 KDA- Role of continuous glucose monitoring in diabetic patients at high cardiovascular risk ÀÌÁØ¿±(°¡Å縯ÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 04¿ù 06ÀÏ Room1 14:10~14:30 KSSO- CVOTs using non-GLP-1 based anti-obesity medications and bariatric surgery È«ÁØÈ(À»ÁöÀÇ´ë ³»ºÐºñ³»°ú)
Åä·Ð 04¿ù 06ÀÏ Room1 14:30~15:00 Panel Discussion ()
ÈÞ½Ä 04¿ù 06ÀÏ 15:00~15:20 Break ()
±³À°½Ã°£ 04¿ù 06ÀÏ Room1,2,3 15:20~16:00 Two key biologic systems for cardiometabolic syndrome based on CAP1 : Resistin & PCSK9 ±èÈ¿¼ö(¼¿ïÀÇ´ë ¼øȯ±â³»°ú)
ÈÞ½Ä 04¿ù 06ÀÏ 16:00~16:10 Break ()
±³À°½Ã°£ 04¿ù 06ÀÏ Room1 16:10~16:30 Dyslipidemia in Elderly-general concept ±è±¤ÁØ(¿¬¼¼ÀÇ´ë ³ë³â³»°ú)
±³À°½Ã°£ 04¿ù 06ÀÏ Room1 16:30~16:50 Dyslipidemia in CKD À¯ÅÂÇö(¿¬¼¼ÀÇ´ë ½ÅÀå³»°ú)
±³À°½Ã°£ 04¿ù 06ÀÏ Room1 16:50~17:10 Dyslipidemia in adolescents and young adults ÀÌÀº¿µ(°¡Å縯ÀÇ´ë ³»ºÐºñ³»°ú)
Åä·Ð 04¿ù 06ÀÏ Room1 17:10~17:40 Panel Discussion ()
±âŸ 04¿ù 06ÀÏ Room1,2,3 17:40~18:00 Closing Ceremony ()